Lonza Group AG (0QNO.L) LSE
Currency In CHF
- General
- Statistics
- Historical Data
- Profile
- Financials
Lonza Group AG
Address
Muenchensteinerstrasse 38
Basel, BW 4002
Switzerland
Phone
41 61 316 81 11
Website
Sector
Healthcare
Industry
Biotechnology
Employees
16866
First IPO Date
March 07, 2006
Key Executives
| Name | Title | Pay | Year Born |
| Wolfgang Wienand | Chief Executive Officer | 0 | 1972 |
| David Carter | Head of Communications | 0 | N/A |
| Gordon Bates | President of Small Molecules Division | 0 | 1965 |
| Jean-Christophe Hyvert | President of Biologics Division | 0 | 1972 |
| Christian Seufert | President of Capsules & Health Ingredients Division | 0 | 1975 |
| Matthias Hofmann | Head of Corporate Environment, Health, Safety & Global Sustainability | 0 | N/A |
| Andreas Bohrer | Chief Legal & Corporate Affairs Officer | 0 | N/A |
| Daniel Buchta | Head of Investor Relations | 0 | N/A |
| Jason Berndt | Executive Vice President & Head of Group Operations | 0 | N/A |
| Philippe Deecke | Chief Financial Officer | 0 | N/A |
| Jennifer Clancy | Senior Director of Global Marketing | 0 | N/A |
| Kim Harrelson | Head of Ethics & Compliance, ERM and Corporate Responsibility | 0 | N/A |
| Nicoleta Baumgartner | Chief Human Resources Officer | 0 | 1971 |
| Victoria Morgan | Head of External Communications | 0 | N/A |
Description
Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and operates mammalian and drug product platforms. Its Advanced Synthesis segment manufactures antibody-drug conjugates (ADCs) and other bioconjugates, small molecules, and highly potent active pharmaceutical ingredients; and operates small molecules and bioconjugates platforms. The Specialized Modalities segment operates various technologies, such as spanning cell & gene, microbial, bioscience, and mRNA. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.
